Amniotic Membrane Allograft Billing: CPT, Q-Codes, and LCD

Amniotic Membrane Allograft Billing: What Every Wound Care Practitioner Needs to Know

Amniotic membrane allografts — dehydrated human amnion/chorion membrane (dHACM) products and related placental-derived cellular tissue products — represent one of the faster-growing segments of the skin substitute market. They also generate a disproportionate share of claim denials. The billing mechanics are not inherently complicated, but the specific documentation requirements, product-level HCPCS Q-code accuracy, and LCD compliance criteria combine to create an environment where incomplete documentation reliably produces a denial.

This post covers the billing structure for amniotic membrane allografts: the CPT application codes, how Q-codes work for these products, what LCD requirements look like, and where claims break down in practice.

The CPT Application Code Framework for Amniotic Membrane Allografts

Amniotic membrane allografts are billed the same way as other cellular and tissue-based products (CTPs): two code types on the same claim — one for the application procedure, one for the product itself.

The application CPT codes depend on anatomical location and wound surface area:

Trunk, arms, legs (non-specialized locations):

15271 — First 25 sq cm or less
15272 — Each additional 25 sq cm (add-on, cannot stand alone)

Face, scalp, eyelids, mouth, neck, ears, hands, feet, fingers, toes:

15275 — First 25 sq cm or less
15276 — Each additional 25 sq cm (add-on, cannot stand alone)

The wound surface area documented in the clinical note must match the code billed. Estimated measurements are not sufficient — CMS requires objective measurement at the time of application. Document length × width in centimeters and record the total surface area used.

Matching Code to Location

The most common CPT-level denial for amniotic membrane allografts is applying a trunk/extremity code (15271) to a wound on the foot. Diabetic foot ulcers (DFUs) — which represent a large share of amniotic membrane allograft use — are foot wounds and belong under 15275/15276. This distinction matters not just for compliance but because the reimbursement rates differ.

For reference on the broader CPT code framework, see the wound care CPT codes 2026 guide.

HCPCS Q-Codes: Product-Specific Billing for Amniotic Membrane Products

Every skin substitute product has its own assigned HCPCS Q-code. For amniotic membrane allografts, Q-codes are billed per square centimeter of product applied. With the 2026 CMS flat rate set at $127.14/sq cm, accurate measurement and accurate Q-code selection directly determine reimbursement.

Getting the Q-code wrong — billing Q4132 (Grafix Core) when the product applied was Epifix — is a billing integrity problem, not just a documentation error. The Q-code must match the actual product used.

Key operational requirements for Q-code accuracy:

The product name, lot number, and exact square centimeter size must be documented in the clinical note and matched to the Q-code on the claim
The quantity units billed must reflect the total sq cm of the product applied to the wound
Unused product does not factor into billing — only the portion applied to the wound bed is billable
Product waste beyond standard application does not create additional billable units

The 2026 CMS flat-rate consolidation affected many amniotic membrane products that previously had individual negotiated rates. Products that were previously high-cost per unit now reimburse at the flat rate regardless of manufacturer list price. This changes the economics of product selection but does not change the coding structure.

LCD Requirements for Amniotic Membrane Allograft Coverage

Medicare Administrative Contractors (MACs) govern coverage of skin substitutes, including amniotic membrane allografts, through Local Coverage Determinations (LCDs). While LCDs vary by MAC jurisdiction, common coverage requirements for these products include:

Wound type eligibility: Most LCDs limit amniotic membrane allograft coverage to chronic, non-healing wounds — primarily diabetic foot ulcers and venous leg ulcers. The wound must meet the definition of chronic, typically documented as full-thickness with measurable depth.

The four-week rule: The wound must be documented as non-healing despite at least four weeks of appropriate standard-of-care treatment. This requires that the medical record show:

The start date of standard wound care
The treatment modalities applied (debridement, appropriate dressings, offloading for DFUs, compression for VLUs)
Serial wound measurements demonstrating less than 40–50% area reduction over that period

Documenting wound measurements at each visit is not optional — it is what establishes the clinical trajectory required for medical necessity.

Comorbidity and vascular documentation: For DFUs, adequate vascular perfusion must be documented before applying an amniotic membrane allograft. Ankle-brachial index (ABI) or toe pressures, or documented clinical assessment of perfusion, should be in the chart. For VLUs, documentation of compression therapy use and reason if not used.

Frequency limitations: Most LCDs limit the number of skin substitute applications per wound episode. Billing a second or third application of an amniotic membrane allograft requires clinical justification in the chart — wound measurements showing partial healing, continued appropriateness of the product, and physician or supervising provider review.

For a full breakdown of LCD structure and how to navigate MAC-specific requirements, see the wound care LCD compliance guide.

Common Denial Triggers Specific to Amniotic Membrane Allografts

In practice, amniotic membrane allograft claims deny for a predictable set of reasons:

Missing four-week documentation trail. A practitioner applies an allograft on visit two after only two weeks of standard care. No documentation exists showing the wound failed to heal over four weeks. The claim denies for lack of medical necessity, and the appeal requires reconstructing documentation that should have been prospectively generated.

Wrong anatomical code. DFU on the plantar surface billed as 15271 instead of 15275. Straightforward fix prospectively, difficult to recover on appeal after the fact.

Q-code mismatch. The product used does not correspond to the Q-code billed. This triggers medical review and potential fraud referral depending on the MAC.

Wound measurement absent or inconsistent. The clinical note says "wound approximately 3 cm" without length × width documentation. The claim has a unit count for the Q-code that cannot be verified against the note.

No documentation of standard care failure. The record shows the wound was treated but does not establish that healing was inadequate. Without wound measurements showing a healing trajectory, the four-week standard-of-care requirement cannot be verified.

Prior authorization not obtained. Several MACs and most Medicare Advantage plans require prior authorization for amniotic membrane allografts. Applying the product without obtaining authorization in advance results in a denial that is generally not recoverable.

Operational Workflow for Clean Claims

The cleanest amniotic membrane allograft claims follow a prospective documentation workflow — not a retrospective one:

At initial wound evaluation: Measure the wound in cm, document wound type, depth, and treatment history. Begin the documented four-week standard-care trial immediately if one is not already in progress.
At each subsequent visit: Record wound measurements. Photograph the wound. Document the treatment applied.
At the application visit: Document the product name, lot number, and quantity applied. Measure the wound immediately before application. Record the CPT code corresponding to the anatomical location. Confirm prior authorization is on file if required by the payer.
At billing: Match Q-code to the exact product used. Bill CPT codes based on the documented location and measured wound area. Attach clinical notes if the payer requires documentation on the initial claim.

This workflow is the same one the skin substitute billing guide recommends for CTPs generally — the only amniotic membrane-specific layer is the product-level Q-code accuracy requirement.

Key Takeaways

Amniotic membrane allografts require two codes: an application CPT (15271–15276 based on location and size) plus a product-specific HCPCS Q-code billed per sq cm at the 2026 flat rate of $127.14/sq cm
The CPT code must match the anatomical wound location — DFUs on the foot use 15275/15276, not 15271/15272
The Q-code must exactly match the specific product applied — mismatches create compliance exposure
LCD coverage requires documented failure of standard wound care for at least four weeks, with serial wound measurements to establish the healing trajectory
Prior authorization is required by most Medicare Advantage plans and some MACs — check before applying the product, not after
Prospective documentation — measurements, treatment records, and product details captured at the time of service — is the only reliable path to clean claims and successful appeals